Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management

This series of peer-to-peer discussions examines the practicalities of personalising heart failure management in the context of recent changes to international clinical practice guidelines.

At this exciting juncture, we now have two SGLT-2 inhibitors that offer clinical benefit across the spectrum of ejection fraction, and an increasing body of real-world and registry-based data showing the clear benefit of early guideline directed medical therapy (GDMT) adoption. In addition, there is a clear move towards the use of patient reported outcomes (PROs) in addition to clinical endpoints. But how can we start to incorporate these changes in current practice?

In this series, our specially selected faculty of experts consider how we can be using these recent developments to personalise our management approach to heart failure and why it matters for better long-term patient outcomes.

Target Audience

This programme is intended to educate:

  • Cardiologists
  • Heart Failure Specialists
  • Primary Care Physicians
  • Nurses
  • Pharmacists
  • Other allied HCPs

Learning Objectives

Upon participation in this programme, physicians will be able to:

  • Review current GDMT in HFrEF and HFpEF
  • Describe the relationship between initiation of GDMT and HF outcomes
  • Prescribe GDMT according to current international recommendations
  • Recall the elements of the Kansas City Cardiomyopathy Questionnaire
  • Describe the clinical studies that support the use of functional and QoL measures in practice
  • Initiate quality of life and functional improvement measures in routine practice
  • Initiate SGLT-2 inhibitors in patients presenting with De novo HF and in patients already on other GDMT
  • Adopt shared decision-making with HF patients



This programme is supported by an unrestricted educational grant from AstraZeneca.



In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organising Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities. 



Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.

The session, ‘Incorporating GDMT and PRO Endpoints for Personalised Heart Failure Management’ is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits. 

Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).

Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.



There is no fee for taking part in this online learning activity.

Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.

To complete the course and claim certification participants must:

  • Read the course outline information supplied and complete pre-test questions if supplied prior to starting the activity. Users must read and study the activity in its entirety before completing the post-test questions.
  • Your results will be automatically saved and if a pass score is achieved (where applicable), you may be eligible to claim credit for the activity and receive a certificate of completion.
Course summary
Available credit: 
  • 1.00 European Board for Accreditation in Cardiology (EBAC)
Course opens: 
Course expires: 

Optimising Clinical Success With Foundational Heart Failure Treatment - Prof Andrew Coats and Dr Mikhail Kosiborod 

Personalising Your Approach to Heart Failure Treatment - Prof Giuseppe Rosano and Dr Biykem Bozkurt

Adopting Patient Reported Outcomes in Heart Failure Management - Dr Mikhail Kosiborod and Dr Shelley Zieroth



Prof Andrew Coats - Heart Research Institute, Sydney, AU

Dr Mikhail Kosiborod - Saint Luke’s Mid America Heart Institute, Kansas City, US

Dr Shelley Zieroth - St Boniface Hospital, Winnipeg, CA

Dr Biykem Bozkurt -  Baylor College of Medicine, Texas, US

Prof Giuseppe Rosano - St George’s University Hospital, University of London, UK

Available Credit

  • 1.00 European Board for Accreditation in Cardiology (EBAC)
Please login or register to take this course.